Advanced Human Imaging Limited Overview
Advanced Health Intelligence is a small Perth-based digital-health software developer. It sells smartphone-based biometric health screening to businesses. The technology combines a patented on-device body-dimensioning engine (BodyScan) with licensed facial blood-flow vital-signs technology (FaceScan, licensed from NuraLogix) and licensed AI dermatology (DermaScan, licensed from Triage Technologies). Together these form a "Biometric Health Assessment" (BHA) that estimates cardiometabolic risk, blood biomarkers and fitness. AHI sells this to insurers, telehealth platforms, pharmacies, employers and governments, either as a white-label product or as embeddable SDKs, under a "Digital Health as a Service" model.
The company has a credible IP base: 19 granted patents at FY2023. Commercial traction, however, has been minimal. Operating revenue was A$0.37M in FY2024 (unaudited), and the business has relied on R&D tax refunds and repeated dilutive raises. A sequence of failures to keep its listings has left it as an unlisted company: Nasdaq equity-deficiency delisting in 2024, then ASX removal in 2025 after the FY2024 accounts were never lodged. It is now a distressed, pre-scale health-tech asset.
What the company does
AHI develops software that turns a standard smartphone into a health-screening device. According to its FY2023 Form 20-F (Item 4B) and FY2024 Appendix 4E, its core offerings are:
-
Body dimension and composition assessment. A full-body "selfie" (front and side images) estimates circumferences, body-fat percentage, waist-to-hip and waist-to-height ratios, and risk of obesity, central obesity and Type 2 diabetes.
-
Blood biomarker prediction. Algorithms estimate total cholesterol, LDL, HDL, triglycerides, HbA1c, C-reactive protein, fasting glucose and 10-year cardiovascular/mortality risk. These came largely from the August 2022 Vertica Health acquisition.
-
Transdermal Optical Imaging (TOI). A 30-second facial video estimates heart rate, heart-rate variability, blood pressure, respiration and stress. This uses technology licensed from NuraLogix Corporation and its DeepAffex cloud engine.
-
On-device dermatological identification. The engine covers 588 skin conditions across 133 categories, including melanoma, and is licensed from Triage Technologies Inc. The underlying Triage software is a Health Canada Class I medical device (June 2020) and is CE-marked under the EU Medical Devices Directive (April 2021).
-
Atrial fibrillation detection. Smartphone-based AFib detection was first listed as an offering in the FY2024 Appendix 4E.
-
Health coaching enablement. Partners can deliver therapeutic and non-therapeutic coaching. This capability came largely from the wellteq acquisition, although the wellteq platform itself was shut in Q4 FY2023.
The flagship integrated product is the Biometric Health Assessment (BHA), a multi-step smartphone workflow:
-
FaceScan plus a demographic and lifestyle questionnaire
-
Resting heart rate measured by photoplethysmography (PPG)
-
BodyScan for body composition
-
A three-minute step test for cardiorespiratory fitness
-
Algorithmic risk outputs for cholesterol, HbA1c, CRP and similar markers
The FY2023 20-F claims the BHA produces 61 health outputs from 41 biometric captures across five categories: cardio-respiratory, body composition, estimated blood biomarkers, metabolic health and mental health. Management presentations in 2024 cited 82 health markers. The difference has not been reconciled publicly.
Business and revenue model
| Revenue mechanism | Description (FY2023 20-F / FY2024 4E) | FY2023 (AUD) | FY2024 unaudited (AUD) |
|---|---|---|---|
| SDK – per user | Fee per enrolled user | 35,495 | 292 |
| SDK – per scan | Fee per completed scan | 2,353 | 26,387 |
| Software subscriptions | Annual/quarterly/monthly licence | 504,708 | 107,675 |
| Integration and development | One-off implementation fees | 107,141 | 234,075 |
| Other revenue (mainly R&D tax incentive and finance-related) | Non-operating | 2,140,740 | 2,313,159 |
AHI describes itself as a B2B "Digital Health as a Service" (dHaaS) provider with a "one-to-one-to-many" structure. AHI licenses its technology to a partner, and the partner owns the relationship with end users. The 20-F lists four ways partners pay:
From 2023, management also moved toward deals priced into the partner's own offering, so AHI is paid regardless of how much end users actually use the technology. One example is the Pharmak Direct digital pharmacy (UAE/Saudi Arabia), where AHI was to earn 1.6% of gross prescription value per Pharmak user (FY2023 20-F risk factors). Large licence-plus-equity structures were also struck. The most notable was the August 2023 China exclusive licence with Changlin Network Technology: a US$10M upfront fee, a US$5M annual fee and a 25% revenue share. No public confirmation has been found that the upfront fee was ever received; an extension was granted in April 2024.
Mix characterisation (analyst view): Revenue is overwhelmingly software and licensing; there are no hardware or physical products. However, "other revenue" (chiefly the refundable Australian R&D Tax Incentive) made up 77% of FY2023 total revenue and 86% of FY2024 total revenue. AHI's reported top line therefore reflects government R&D rebates more than commercial sales.
Value-chain position, customers and end markets
AHI sits at the technology/IP layer of digital health. It supplies embeddable measurement and risk algorithms to platform owners rather than running consumer apps itself. The exception was the wellteq corporate-wellness platform, which AHI acquired in late 2022 and shut in mid-2023.
Customer types and end markets disclosed in the 20-F:
-
mHealth, telehealth and wellness platforms
-
Life and health insurers and reinsurers (the Unisure/SCOR letter of intent)
-
Digital pharmacies (Pharmak Direct)
-
Employers and corporate wellness (via wellteq, Bearn LLC)
-
Governments and population-health programmes (Saudi Arabia via IntelliGen; Singapore Healthcare InnoMatch; China via Changlin)
-
Earlier: fitness and consumer apparel (the BodyScan sizing heritage)
Company's own description, paraphrased (FY2024 Appendix 4E): AHI aims to become a global leader in digital health by using the ubiquity of smartphones to provide health-screening and triage tools to providers, carers, insurers and governments. Its stated mission is better outcomes, better health literacy and earlier detection of chronic disease.
Independent characterisation: AHI is a sub-scale, pre-commercial health-AI licensing business. Its proprietary core (BodyScan) is narrow. A significant part of its headline capability (FaceScan, DermaScan) is licensed from third parties on a non-exclusive basis, which limits defensibility. Its go-to-market has depended heavily on announced memoranda, letters of intent and partner launches that have rarely converted into material recurring revenue. In September 2023 it had to retract an announcement that wrongly implied a relationship with AIG.
Strategy
Stated strategy (themes from FY2023 20-F and FY2024 Appendix 4E)
-
Become a global digital-health leader in smartphone health screening, focused on early identification of chronic-disease risk and digital triage into "right-care pathways".
-
Population-scale deployment through governments, explicitly tied to Saudi Vision 2030's Health Sector Transformation Program (via IntelliGen) and China's "Healthy China 2030" agenda (via Changlin).
-
On-device AI to cut cloud costs, latency and privacy risk. The company cites about 3.7 billion AI-capable smartphones.
-
Revenue de-risking, by pricing AHI into partner offerings (Pharmak revenue share) instead of relying on end-user usage.
-
Clinical validation and regulatory approval: the Stellenbosch University study, an FDA 513(g) inquiry, and a long-term aim of FDA 510(k) clearance for the BHA as software as a medical device.
-
Insurance digital underwriting with Unisure and SCOR, using digital biomarkers in place of blood tests.
Initiatives in the last 24 months (Oct 2024 – Oct 2026) and the preceding build-up
| Initiative | Date | Target / detail | Status |
|---|---|---|---|
| ASX reinstatement plan | Jun 2024 – Sep 2025 | ASX required A$4M of cleared funds plus lodgement of the outstanding reports | Failed: removed from ASX on 1 Oct 2025 |
| Nasdaq appeal and relisting strategy | Aug 2024 – Jul 2025 | Restore stockholders' equity above US$2.5M; relist after ASX reinstatement | Failed: delisting confirmed 2 Jul 2025 |
| A$15M funding package | 15 Apr 2024 | Placement, convertible notes, R&D advance, US shelf | Partially executed (about A$2.8M equity and A$1.5M notes received in FY2024) |
| US$4M convertible note facility | 30 Jan 2025 | Working capital | Drawdown status not publicly disclosed |
| Oakley Capital Partners commitment up to A$5.5M | 2025 (exact date not confirmed) | Placement plus convertible note for reinstatement; also targeted US$6M from strategic investors and up to A$3M in R&D grants | Outcome not publicly disclosed |
| Cost-reduction programme | FY2023 – FY2025 | A$4.8M annualised savings after acquisitions (Q4 FY2023); further cuts during FY2024 | Partly achieved (FY2024 G&A −37%) |
| MENA expansion | 2023 – 2025 | IntelliGen SPV, Pharmak MSA, Bin Farhood introductions | Revenue not disclosed |
| China licence (Changlin) | Aug 2023 – Apr 2024 | US$10M upfront fee | Extension granted Apr 2024; receipt unconfirmed |
| Leadership reset | 16 Sep 2025 | Garnett (science- and insurance-oriented founder) becomes CEO | Ongoing |
| Post-delisting plan | From Jul 2025 | Operate as an unlisted company, seek funding, assess alternative exchanges | Ongoing; no public update found |
ESG commitments: None publicly disclosed.
Medium-term financial targets: In 2023 management said it was targeting cash-flow breakeven in calendar 2023 (Q3 FY2023 commentary). That target was missed by a wide margin. The OneClinic partnership targeted 1 million paid users in its first year after launch; no outcome has been reported. No current guidance exists.
Products & Services
All products sit within the single "technological development" segment.
Pricing levels are not publicly disclosed. The only disclosed commercial rates are:
-
Pharmak Direct: 1.6% of gross prescription value
-
Changlin: US$10M upfront, US$5M annual fee and a 25% revenue share
-
IntelliGen: receives 50% of revenue above AHI's base commercial offering
Product Portfolio
| Product | Description and capabilities | Target customer | Origin / IP status | Launch / latest version | Pricing model |
|---|---|---|---|---|---|
BodyScan | On-device "full body selfie": front and side images taken with 10-second countdowns in burst mode. Returns circumferences, total body-fat %, waist-hip and waist-height ratios, Type 2 diabetes, obesity and central-obesity risk. Images are processed and deleted on the device | Insurers, telehealth, fitness, apparel, governments | Proprietary and patented (priority date Dec 2014). Section 513(g) FDA inquiry filed 2023 for obesity identification and tracking | Original MyFiziq product (c. 2015); on-device GPU version and later releases | Per scan, per user, subscription |
FaceScan | 30-second facial video using transdermal optical imaging. Estimates heart rate, HRV, blood pressure, stress, respiratory rate, and CVD, heart-attack and stroke risk. Processed on the NuraLogix DeepAffex cloud | Telehealth, insurers, pharmacies | Non-exclusive licence and reseller agreement with NuraLogix Corporation | Integrated c. 2020–2021 | Bundled within the SDK |
DermaScan | AI identification of 588 skin conditions across 133 categories, including all skin-cancer categories. Positioned as a second-opinion tool for clinicians | Telehealth, clinicians, insurers | Non-exclusive licence from Triage Technologies (Health Canada Class I; CE-marked; US patent Dec 2020) | Term sheet Oct 2020; integrated 2021 | Bundled within the SDK |
CompleteScan (MultiScan platform) | Single SDK bundling BodyScan, FaceScan and DermaScan, with user authorisation, billing events, remote asset download and payment registration. iOS and Android | All partners | Proprietary wrapper | 2,021 | Per scan / subscription |
Biometric Health Assessment (BHA) | Five-step smartphone assessment (FaceScan plus questionnaire, PPG resting heart rate, BodyScan, 3-minute step test, analysis) producing 61 outputs from 41 captures (FY2023 20-F) | Governments, insurers, pharmacies, primary care | Proprietary combination of in-house and licensed components | SDK and app announced 2023 (Q3 FY2023 commentary) | Licence plus per-assessment; revenue share in MENA and China |
Health Risk Assessment Report (HRA) / digital blood biomarkers | Estimates total cholesterol, LDL, HDL, triglycerides, CRP, visceral adiposity index, lipid accumulation product, fasting glucose, metabolic-syndrome components, brachial-ankle pulse wave velocity and 10-year CVD risk | Insurers (digital underwriting), population health | From the Vertica Health acquisition (Aug 2022) | 2022–2023 | Bundled |
Atrial fibrillation detection | Smartphone-based detection and monitoring of AFib | Cardiology and telehealth partners | Disclosed in FY2024 4E; IP origin not detailed | FY2024 | — |
Health coaching enablement (ex-wellteq) | Personalised therapeutic and non-therapeutic coaching and health-literacy programmes | Employers, insurers | From the wellteq acquisition; wellteq platform sales ceased Q4 FY2023 | 2022; discontinued as standalone 2023 | Previously subscription |
White-label apps / partner brands | Partner-branded apps embedding AHI technology. TradingView lists associated brands ACTIVATE, HEALTH i CHECK, TINJOY, Nexus–Vita, MVMNT and BEARN, most of which appear to be partner or channel brands rather than AHI-owned products | Channel partners | Mixed | Various | — |
“—” = not publicly disclosed.
Financial Narrative
Sources by year:
-
FY2020–FY2021: Kalkine aggregator data and ASX releases (net loss for FY2021 confirmed in the FY2022 annual report)
-
FY2022–FY2023: audited FY2023 Form 20-F and reissued FY2022 annual report
-
FY2024: unaudited Appendix 4E (2 Sep 2024)
FY2020–FY2021 operating revenue comes from an aggregator and should be read as indicative. Where no figure is available for a year, that year is left out of the table rather than estimated.
Income statement
Notes:
-
Gross profit is not reported. AHI presents expenses by nature and has no cost-of-sales line, so a gross margin cannot be calculated.
-
Underlying FY2023 EBITDA adds back A$0.476M of impairment and the A$1.808M Triage fair-value loss.
-
EPS (basic/diluted) for FY2022–FY2024 is not disclosed in the sources reviewed (FY2024 weighted average shares not published). Aggregator data (Macrotrends) shows a loss per ADS but on an inconsistent basis, so it is excluded.
-
Dividends per share: zero in every year. AHI has never paid a dividend (FY2024 4E Note 8). Dividend records shown under the "AHI" code on some Australian portals (2007–2008) belong to Allco HIT Limited, a previous holder of the ticker, and do not relate to this company.
Margins.
Revenue CAGR. Operating revenue grew from A$0.14M (FY2020) to A$0.368M (FY2024), a four-year CAGR of about 27%. The path was erratic: a peak of A$0.65M in FY2023 followed by a 43% decline.
Balance sheet
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue Lines
| Revenue line (AUD Mn) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Software income | 0.015 | 0.543 | 0.134 |
Integration and development income | 0.183 | 0.107 | 0.234 |
Operating revenue | 0.197 | 0.650 | 0.368 |
Other revenue (incl. R&D tax incentive) | 1.136 | 2.141 | 2.313 |
Total revenue | 1.333 | 2.790 | 2.682 |
Results by Segment and Segment Margins & Growth (%)
| Segment metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Operating loss (AUD Mn) | -20.07 | -12.60 | -3.69 |
Pre-tax loss (AUD Mn) | -20.08 | -12.83 | -4.15 |
Operating revenue YoY growth (%) | — | 229.4 | -43.3 |
Total revenue YoY growth (%) | — | 109.3 | -3.9 |
Contribution to group revenue (%) | 100 | 100 | 100 |
Group Entities
| Entity | Jurisdiction | Ownership | Function | Source |
|---|---|---|---|---|
Advanced Health Intelligence Ltd | Australia | Parent | IP owner, HQ, listed entity (historical) | 20-F |
Vertica Health (Pty) Ltd | South Africa (Stellenbosch) | 100% | Biomarker and risk algorithms, science team | FY2024 4E |
Wellteq Digital Health Inc. and subsidiaries | Canada (British Columbia) and others | 100% | Former corporate-wellness platform (discontinued Q4 FY2023) | FY2024 4E |
Body Composition Technologies Pte Ltd | Singapore | 53% (from 7 Feb 2024) | Body-composition IP (licence IP A$3.25M on consolidation) | FY2024 4E |
US subsidiary | United States | 100% | Named only generically in the 20-F (CFC risk factor) | 20-F |
AHI UAE / MENA SPV entities | UAE | — | Vehicle for IntelliGen/MENA opportunities | 20-F; FY2024 4E |
Changlin Network Technology Ltd | China (Shanghai) | 50% intended under licence terms | China licensee; equity status unconfirmed | 20-F |
“—” = not publicly disclosed.
Income Statement
| Metric (AUD Mn) | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Operating revenue | 0.14 | 0.59 | 0.197 | 0.650 | 0.368 |
Net loss after tax | -5.40 | -14.06 | -20.08 | -12.83 | -4.15 |
Income Statement (FY2022–FY2024)
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Total revenue incl. other revenue | 1.333 | 2.790 | 2.682 |
Employee expenses | 11.76 | 5.86 | 6.37 |
General administration | 4.17 | 3.21 | 2.02 |
Operating loss (EBIT proxy) | -20.07 | -12.60 | -3.69 |
Pre-tax loss | -20.08 | -12.83 | -4.15 |
Income Statement (FY2023–FY2024)
| Metric (AUD Mn) | FY2023 | FY2024 |
|---|---|---|
Sales and marketing | 0.910 | 1.476 |
Depreciation and amortisation | 0.313 | 0.358 |
EBITDA (operating loss + D&A) | -12.29 | -3.33 |
Impairment / (write-back) | 0.476 | -5.375 |
Underlying EBITDA excl. impairment and Triage fair-value items | -10.00 | -8.70 |
Insurance expense | 1.825 | 1.120 |
Finance costs | 0.478 | 0.688 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Operating loss / total revenue | -1,505 | -452 | -137 |
Net loss / total revenue | -1,506 | -460 | -155 |
Net loss / operating revenue | -10,191 | -1,974 | -1,127 |
Balance Sheet
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Cash and equivalents | 6.01 | 2.10 | 0.026 |
Total equity | 8.56 | 2.03 | 3.28 |
Balance Sheet (FY2023–FY2024)
| Metric (AUD Mn) | FY2023 | FY2024 |
|---|---|---|
Total current assets | 3.25 | 0.61 |
Total assets | 8.91 | 15.20 |
Goodwill | 3.21 | 4.10 |
Total intangibles incl. goodwill | 4.31 | 7.84 |
Investments (incl. Triage at fair value) | 0.76 | 6.11 |
Trade and other payables | 3.47 | 7.56 |
Short-term debt (borrowings + interest-bearing) | 1.43 | 0.65 |
Long-term debt | 0.00 | 1.49 |
Total debt (excl. leases) | 1.43 | 2.14 |
Net debt (positive = debt) | -0.67 | 2.11 |
Total current liabilities | 6.03 | 9.50 |
Total liabilities | 6.88 | 11.92 |
Working capital | -2.78 | -8.89 |
Accumulated losses | -75.30 | -79.45 |
Issued capital | 76.01 | 79.53 |
Cash Flow
| Metric (AUD Mn) | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Operating cash flow | -2.70 | -4.10 | -9.86 | -7.37 | -4.75 |
Financing cash flow | 2.84 | 9.12 | 17.08 | 4.17 | 2.78 |
Cash Flow (FY2021–FY2024)
| Metric (AUD Mn) | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Capex (PP&E) | 0.023 | 0.086 | 0.172 | 0.002 |
Free cash flow (OCF − capex) | -4.12 | -9.95 | -7.54 | -4.75 |
Returns & Leverage Ratios
| Metric (AUD Mn) | FY2023 | FY2024 |
|---|---|---|
R&D tax incentive received (in OCF) | 2.03 | 2.31 |
Receipts from customers | 0.82 | 0.13 |
Proceeds from share issues | 5.00 | 2.79 |
Proceeds from convertible notes | 1.98 | 1.50 |
Investing cash flow | -0.67 | -0.10 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 |
|---|---|---|
ROE (%, on average total equity) | -242 | -156 |
ROA (%, on average total assets) | -144 | -34 |
Current ratio (x) | 0.54 | 0.06 |
Debt / equity (x) | 0.71 | 0.65 |
Asset turnover (operating revenue / avg assets, x) | 0.07 | 0.03 |
Region (Qualitative) Overview
| Region (qualitative) | Evidence of commercial activity | Trend |
|---|---|---|
Australia / NZ | HQ; R&D tax incentive (main "other revenue") | Stable government rebates |
North America | wellteq (Canada, discontinued); Bearn LLC, OnCore Innovations, Kalibra (USA) | Declining after wellteq closure |
Europe | Inter-Psy / Health i Check (Netherlands); Unisure/SCOR LOI | Unclear |
Middle East / North Africa | Pharmak Direct (UAE, KSA), IntelliGen (KSA), Bin Farhood Group (UAE) | Stated strategic priority FY2024–FY2025; MSA delayed by the ASX suspension |
Asia | Changlin (China; licence fee unconfirmed), BCT (Singapore), Singapore InnoMatch finalist, OneClinic | Stated priority for 2024 funding |
Africa | Vertica Health (South Africa); Stellenbosch University study | R&D hub |
Share Price & Returns
| Reference point | Price | Date | Source |
|---|---|---|---|
ASX all-time low | A$0.030 | 9 Oct 2017 | TradingView |
ASX all-time high | A$2.19 | 3 Mar 2021 | TradingView |
ASX last traded / suspended price | A$0.092 | Early 2024 (suspended until removal on 1 Oct 2025) | InvestSMART / TradingView |
Nasdaq IPO marketed range | US$7–9 per ADS (1:7 ratio) | Oct 2021 | Renaissance Capital |
Nasdaq first-day return | -59.7% | Nov 2021 | Renaissance Capital |
Nasdaq last ADS price | US$1.50 (1:28 ratio) | 2024 | Yahoo Finance / Tiger |
Change since Nasdaq IPO | -91.13% | At delisting | Simply Wall St |
Performance (ASX, %) | Value | — | — |
Last price vs all-time high (Mar 2021) | -95.8 | — | — |
1-year return to Oct 2026 | Not meaningful (no trading) | — | — |
3-year return to Oct 2026 | Not meaningful (no trading after early 2024) | — | — |
5-year return to Oct 2026 | Not meaningful (no trading after early 2024) | — | — |
Capital Instruments
| Instrument | Amount (AUD Mn) | Maturity |
|---|---|---|
Current borrowings | 0.40 | < 12 months |
Current interest-bearing borrowings | 0.25 | < 12 months |
Non-current borrowings | 1.49 |
|
Lease liabilities | 0.31 | 2026–2028 (office lease, 7.8% IBR) |
Deferred acquisition consideration | 0.58 | Current |
US$4M convertible facility (Jan 2025) | Drawn amount not disclosed | — |
“—” = not publicly disclosed.
Analyst Conclusions
Guidance and consensus
Management guidance: None. The last stated targets were cash-flow breakeven in 2023 (missed) and 1M paid users via OneClinic (unreported).
Consensus growth expectations: None. There is no active analyst coverage.
Bull case
-
Hidden asset value. The Triage stake (A$5.55M unaudited) plus BCT licence IP (A$3.25M) and a 19-patent portfolio could exceed the company's entire last market value of about A$20–23M in a trade sale or break-up.
-
Optionality from large licences. A single funded deal of the Changlin type (US$10M upfront, US$5M a year) would transform a business whose FY2024 operating revenue was A$0.37M.
-
Lean new cost base under insurance-savvy leadership. FY2024 G&A was cut 37%, and CEO Garnett's insurer background (Metropolitan Health, Bryte) fits the digital-underwriting opportunity with reinsurers such as SCOR.
Bear case
-
Solvency. Cash of A$25,757 against current liabilities of A$9.50M (30 June 2024), with no audited accounts and no public market to raise equity, points to a high probability of further distress or administration.
-
Credibility. Unclosed headline deals (Changlin), the AIG retraction, two restatements of FY2022 accounts and the failure to lodge FY2024 accounts undermine trust with partners and investors.
-
Thin moat. Two of the three headline scans are non-exclusive licences, and rPPG and body-scan SDKs are becoming commoditised as big-tech phones add native health sensing.
Catalysts and monitorables (next 12 months)
-
Publication of audited FY2024 and FY2025 accounts, if any
-
Any capital raise or completed Oakley / strategic-investor funding
-
Confirmation or termination of the Changlin licence and fee receipt
-
A trade sale or monetisation of the Triage stake
-
Any application to list on an alternative exchange
-
FDA 513(g) response or a 510(k) submission
-
Revenue from Pharmak, IntelliGen or Bearn
-
Shareholder communications on solvency or any administration
Analyst verdict
Advanced Health Intelligence, formerly Advanced Human Imaging and before that MyFiziq, is a cautionary example of an innovation-rich but commercially unproven health-tech microcap. Over roughly a decade it built a credible on-device body-dimensioning patent family. It then assembled, through licences and small acquisitions, a broad smartphone health-assessment suite covering vitals, skin, fitness and modelled blood biomarkers. The science appears to be serious, and its use of on-device processing anticipated today's privacy-first AI trend.
The financial record is harder to defend. From FY2020 to FY2024 the company lost about A$56M at the net level and burned about A$29M in operating cash. Its best year produced only A$0.65M of operating revenue (FY2023). Reported revenue has been sustained mainly by the Australian R&D Tax Incentive. Management repeatedly announced transformative deals (a US$10M China licence, MENA government channels, insurer partnerships), but the public record does not show these converting into cash. Governance lapses then compounded the commercial shortfall: a retracted press release, restated accounts, and finally the failure to lodge audited FY2024 accounts. That sequence cost AHI its Nasdaq listing in 2024–2025 and its ASX listing on 1 October 2025.
As of October 2026, AHI should be treated as a distressed private company, not an investable listed equity. Any residual value lies in its patents, its Triage stake and its clinical-insurance know-how. That value is most likely to be realised through a trade sale, recapitalisation or licensing transaction rather than organic growth. For counterparties, the key diligence items are audited solvency, the enforceability of key licences (NuraLogix, Triage) and evidence of paying customers.
Overall stance: High risk / speculative. Information quality is too low and solvency too uncertain for a valuation-based recommendation.
Principal sources consulted
-
Advanced Health Intelligence Ltd, Form 20-F for FY2023 (SEC, filed 31 Oct 2023): https://www.sec.gov/Archives/edgar/data/1815436/000121390023081853/f20f2023_advancedhealth.htm
-
Form 20-F for FY2022 (SEC): https://www.sec.gov/Archives/edgar/data/1815436/000121390023007932/f20f2022_advancedhealth.htm
-
Appendix 4E and Preliminary Final Report FY2024, unaudited (ASX, 2 Sep 2024): https://announcements.asx.com.au/asxpdf/20240902/pdf/067cwk85kxsxdg.pdf
-
Half-Year Financial Report 31 Dec 2023 (SEC 6-K): https://www.sec.gov/Archives/edgar/data/1815436/000121390024062876/ea020963301ex99-1_advanced.htm
-
Appendix 4D H1 FY2023 (ASX): https://www.asx.com.au/asxpdf/20230228/pdf/45m5rm66lhztbk.pdf
-
Appendix 4D H1 FY2022 (ASX): https://www.asx.com.au/asxpdf/20220228/pdf/456jww4zydzrf1.pdf
-
Release of 2022 Annual Report (ASX, 12 Oct 2022): https://announcements.asx.com.au/asxpdf/20221013/pdf/45g7gg2cx4h6n0.pdf
-
Reissued 2022 Annual Report (ASX, 15 Dec 2022): https://www.asx.com.au/asxpdf/20221215/pdf/45jw045z7cybzj.pdf
-
Nasdaq Update 6-K (14 Jul 2025): https://www.sec.gov/Archives/edgar/data/1815436/000121390025064066/ea024887701ex99-1_advanced.htm
-
ASX Compliance, Removal from Official List (1 Oct 2025): https://announcements.asx.com.au/asxpdf/20251001/pdf/06pz3cbfdsmmtx.pdf
-
Nasdaq Determination release (1 Aug 2024): https://wcsecure.weblink.com.au/pdf/AHI/02834768.pdf
-
Shareholder Equity Compliance Update (10 May 2024): https://www.aspecthuntley.com.au/asxdata/20240510/pdf/02805879.pdf
-
ASX reinstatement conditions 6-K (20 Jun 2024): https://www.sec.gov/Archives/edgar/data/1815436/000121390024054118/ea020817001ex99-1_advanced.htm
-
Retraction release (29 Sep 2023): https://www.newsfilecorp.com/release/182480
-
wellteq arrangement release: https://www.newsfilecorp.com/release/135781
-
MobiHealthNews on the wellteq takeover and management change: https://www.mobihealthnews.com/news/anz/advanced-human-imaging-announces-management-shakeup-following-wellteq-takeover
-
Q3 and Q4 FY2023 quarterly commentaries (Newsfile): https://www.newsfilecorp.com/release/164352 and https://www.newsfilecorp.com/release/175638
-
InvestSMART ASX announcement index: https://www.investsmart.com.au/security/asx/ahi/advanced-health-intelligence-ltd/announcements
-
Renaissance Capital, IPO terms and profile: https://www.renaissancecapital.com/Profile/AHI
-
IPOScoop: https://www.iposcoop.com/ipo/advanced-human-imaging-ltd
-
TradingView: https://www.tradingview.com/symbols/ASX-AHI
-
Yahoo Finance profile: https://es-us.finanzas.yahoo.com/quote/AHI/profile
-
MarketScreener (Dylan Garnett): https://www.marketscreener.com/insider/DYLAN-R-GARNETT-A0TGII/
-
Kalkine financial summary: https://kalkine.com.au/company/asx-ahi
-
Tiger Brokers: https://www.itiger.com/stock/AHI/news
-
Simply Wall St: https://simplywall.st/stocks/us/healthcare/nasdaq-ahi/advanced-health-intelligence
-
TipRanks announcement summaries (ASX delisting; Oakley funding)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / dates | Background | Birth year | Total remuneration (latest reported) |
|---|---|---|---|---|---|
Dylan R. Garnett | Chief Executive Officer | CEO from 16 Sep 2025; corporate officer from 19 Dec 2022 (Chief Innovation Officer) | Founder of Vertica Health. Former CEO of Metropolitan Health Group, MD of Metropolitan Health Risk Management, COO of Bryte Insurance (2011–2012). BCom(Hons), BSc(Hons) | 1976 | — |
Scott Montgomery | Former CEO and Executive Director | CEO Dec 2022 – Sep 2025; left the board Sep 2025 | Co-founder and CEO of wellteq. Trained exercise physiologist; about 20 years in B2B health | 1982 | ~240k (Yahoo Finance; currency not stated) |
Dr Katherine Iscoe | Co-founder, Executive Director | Co-founder; CEO until Dec 2022 | BA, BA, MSc, MSc, PhD | 1979 | ~187k (Yahoo Finance) |
Vlado Bosanac | Founder and Head of Strategy | Co-founder (2014) | Corporate strategy | 1966 | ~260k (Yahoo Finance) |
Simon Durack | CFO and Company Secretary | From at least 2022 | BCom, FCA, FCIS, JP | 1962 | ~182k (Yahoo Finance) |
Nick Prosser | Non-Executive Chairman | Chair by Aug 2024 (appointment date not disclosed in sources) | — | — | — |
Dr Peter Vaughan | Non-Executive Director | From Dec 2022 (former wellteq chair) | Health and digital governance | — | — |
Edward Greissing Jr | Non-Executive Director | — | US-based; joined at Nasdaq listing | — | — |
Terence Stupple | Chief Technology Officer | — | Technology | 1979 | — |
Dr Riaan Conradie | Chief Science Officer | Not disclosed (likely joined via Vertica) | PhD | — | — |
Anita Swan | Marketing Director | — | Marketing | — | — |
Nadine Amesz | Head of Operations | — | Operations | — | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder category | Stake | Date | Source |
|---|---|---|---|
Management and board (shares, rights and options) | ~22.6% | 30 Jun 2023 | FY2023 20-F |
Single largest shareholder (unnamed) | ~15.6% of ordinary shares | 30 Jun 2023 | FY2023 20-F |
US residents (incl. ADS holders) | ~2.41% | 30 Jun 2023 | FY2023 20-F |
Institutional ownership (top 10) | Not publicly disclosed; negligible institutional presence | — | — |
Competitive Landscape
Competitors by Segment
| Category | Competitor | HQ | Positioning vs AHI |
|---|---|---|---|
Camera-based vital signs (rPPG/TOI) | NuraLogix (also AHI's licensor) | Canada | Owns the TOI/DeepAffex IP AHI resells; can sell directly to the same customers |
Camera-based vital signs | Binah.ai | Israel | Video-based vitals SDK for insurers and telehealth |
Camera-based vital signs | Lifelight (Xim Ltd) | UK | Contactless vitals; NHS pilots |
Camera-based vital signs | Shen.AI | Poland / global | rPPG SDK |
Smartphone body scanning | 3DLOOK | USA / Ukraine | Body measurement for apparel and health |
Smartphone body scanning | Bodygram | USA / Japan | Body measurement SDK |
Body scanning (hardware and app) | Size Stream / Styku / Fit3D | USA | 3D body-composition scanners for gyms and clinics |
Skin-AI | SkinVision | Netherlands | Consumer skin-cancer risk app (CE-marked) |
Skin-AI | Miiskin / First Derm | Denmark / Sweden | Dermatology apps |
Health-risk platforms | dacadoo | Switzerland | Health score and engagement platform for insurers |
Big-tech platforms | Apple Health, Google Fitbit, Samsung Health | USA / Korea | Native sensor-based health metrics; potential substitutes |
Competitor Detail
| Metric | AHI FY2024 |
|---|---|
Operating revenue (AUD Mn) | 0.368 |
Operating revenue growth (%) | -43.3 |
Net margin vs total revenue (%) | -155 |
Recent Developments
Note on coverage: * Disclosure largely stopped after AHI's ASX removal on 1 October 2025. As an unlisted company, AHI has no continuous-disclosure obligation, and no material public announcements dated after October 2025 were found. The register therefore covers January 2024 to October 2026 so that it holds enough entries to be useful.



